Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients who have inoperable or metastasized endocrine tumors. Symptomatic improvement may occur with all (111)In-, (90)Y-, or (177)Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy. The results that were obtained with [(90)Y-DOTA degrees ,Tyr(3)]octreotide and [(177)Lu-DOTA degrees ,Tyr(3)]octreotate are encouraging in tumor regression. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild. These data compare favorably with the limited number of alternative treatment approaches.
Kwekkeboom
Dik J
DJ
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. lfeun@med.miami.edu
Teunissen
Jaap J M
JJ
Kam
Boen L
BL
Valkema
Roelf
R
de Herder
Wouter W
WW
Krenning
Eric P
EP
D004701:Endocrine Gland Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D007205:Indium Radioisotopes; D008187:Lutetium; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods; D015021:Yttrium Radioisotopes
D007205:Indium Radioisotopes; D015021:Yttrium Radioisotopes; D008187:Lutetium; D015282:Octreotide